Phase 3 Readout

FDMT: Phase 3 Topline: A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of

Name: Phase 3 Topline: A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of
Start: 2028-06-01
End: 2028-06-01

June 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: June 1, 2028
Company: 4D Molecular Therapeutics, Inc. (FDMT)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of

June 1, 2028

FDMT overview →

Company: 4D Molecular Therapeutics, Inc. (FDMT)
Indication: Macular Neovascularization Secondary to Age-Related Macular Degeneration